Financial Comparison: Calithera Biosciences (CALA) versus ADMA Biologics (NASDAQ:ADMA)
ADMA Biologics (NASDAQ: ADMA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitabiliy, risk and valuation.
This table compares ADMA Biologics and Calithera Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
ADMA Biologics has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 3.35, indicating that its stock price is 235% more volatile than the S&P 500.
Institutional and Insider Ownership
71.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 54.2% of Calithera Biosciences shares are owned by institutional investors. 60.4% of ADMA Biologics shares are owned by insiders. Comparatively, 16.3% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares ADMA Biologics and Calithera Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|ADMA Biologics||$11.17 million||4.29||-$18.64 million||($1.70)||-2.19|
|Calithera Biosciences||$4.19 million||150.36||-$33.84 million||($1.66)||-10.75|
ADMA Biologics has higher revenue and earnings than Calithera Biosciences. Calithera Biosciences is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations for ADMA Biologics and Calithera Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ADMA Biologics currently has a consensus price target of $13.00, indicating a potential upside of 249.46%. Calithera Biosciences has a consensus price target of $14.40, indicating a potential downside of 19.33%. Given ADMA Biologics’ higher possible upside, equities research analysts clearly believe ADMA Biologics is more favorable than Calithera Biosciences.
Calithera Biosciences beats ADMA Biologics on 7 of the 13 factors compared between the two stocks.
About ADMA Biologics
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company’s lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.